OAM
FATE icon

Oxford Asset Management’s Fate Therapeutics FATE Stock Holding History

Oxford Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-41,289
Closed -$530K – 1754
2018
Q4 		$530K Buy
+41,289
New +$576K 0.01% 1172
2017
Q4 		– Sell
-78,126
Closed -$318K – 1689
2017
Q3 		$318K Sell
78,126
-15,457
-17% -$52.6K 0.01% 1328
2017
Q2 		$303K Buy
+93,583
New +$359K 0.01% 1255
2016
Q1 		– Sell
-51,745
Closed -$173K – 832
2015
Q4 		$173K Buy
+51,745
New +$217K ﹤0.01% 810

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Oxford Asset Management's FATE Position: Q1 2019 in Review

Oxford Asset Management sold out of Fate Therapeutics (FATE) in Q1 2019, closing a stake of 41,289 shares — an estimated $530K sold.

Oxford Asset Management first reported a position in FATE in Q4 2015 and held it in 4 quarters. The position peaked at $530K in Q4 2018. 123 funds tracked by Wall St. Rank hold FATE as of Q1 2019.

  • Oxford Asset Management reported no remaining Fate Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 41,289 Fate Therapeutics shares in Q1 2019, an estimated $530K.
  • Oxford Asset Management first reported a position in Fate Therapeutics in Q4 2015 and held it in 4 quarters.
  • Oxford Asset Management's Fate Therapeutics position peaked at $530K in Q4 2018.
  • 123 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.